pharmanewsdaily

Castle Creek acquisition of Fibrocell : Castle Creek Pharmaceutical Holdings (CCP Holdings) has agreed to acquire Fibrocell Science, a cell and gene therapy company engaged in developing autologous cell-based therapies for skin and connective tissue disorders. Financial terms of the deal were not disclosed, as per the latest pharma industry news. CCP Holdings is a […]

The post Castle Creek to acquire cell and gene therapy company Fibrocell appeared first on PharmaNewsDaily.com.

FeDeriCa clinical trial results : Roche’s Genentech reported that the phase 3 FeDeriCa study evaluating the investigational fixed-dose combination (FDC) of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase in HER2-positive breast cancer met its primary endpoint. The Perjeta and Herceptin combination, which was subcutaneously injected in combination with intravenous (IV) chemotherapy, showed non-inferior levels of […]

The post FeDeriCa clinical trial results : Phase 3 trial in HER2-positive breast cancer meets primary endpoint appeared first on PharmaNewsDaily.com.

Eisai and Biogen have decided to stop the MISSION AD1 and AD2 phase 3 clinical studies on elenbecestat in early Alzheimer’s disease (AD) owing to safety concerns, as per the latest clinical trial news. The decision has been driven by the findings of a safety review undertaken by the Data Safety Monitoring Board (DSMB), which […]

The post Eisai, Biogen to scrap elenbecestat phase 3 studies in early AD appeared first on PharmaNewsDaily.com.

RESTORE clinical trial of STR001 : Swiss biopharma company Strekin has wrapped up patient enrollment in a phase 3 study, called RESTORE, for evaluating its small molecule STR001 in patients after a sudden sensorineural hearing loss (SSNHL) event. The late-stage trial is a global, randomized, placebo-controlled study, which will feature 165 patients at nearly 25 […]

The post RESTORE clinical trial of STR001 : Strekin completes patient enrollment appeared first on PharmaNewsDaily.com.

CroíValve, an Irish medtech company spun out from Trinity College, has raised €4 million for developing a medical device called Tricuspid Coaptation Valve for the treatment of tricuspid regurgitation (TR), a severe heart condition. The financing secured by the Irish medtech firm includes €2.5 million from the European Union under its Horizon 2020 SME Instrument […]

The post CroíValve set to advance Tricuspid Coaptation Valve into clinical trial appeared first on PharmaNewsDaily.com.

Aytu acquisition of Innovus : Colorado-based specialty pharma company Aytu BioScience has agreed to acquire Innovus Pharmaceuticals in a deal worth up to $24 million, as per the latest pharma acquisition news. Headquartered in California, Innovus Pharmaceuticals is an over the counter (OTC) consumer goods and specialty pharmaceutical company. On the other hand, Aytu BioScience […]

The post Aytu BioScience to acquire Innovus Pharmaceuticals appeared first on PharmaNewsDaily.com.

GVOKE FDA approval : Xeris Pharmaceuticals has bagged approval from the US Food and Drug Administration (FDA) for GVOKE (glucagon) injection for the treatment of severe hypoglycemia associated with diabetes in people, aged two years and above. GVOKE is a ready-to-use, room-temperature stable liquid glucagon. It is now the first FDA-approved glucagon product that can […]

The post Xeris Pharmaceuticals bags GVOKE FDA approval for severe hypoglycemia appeared first on PharmaNewsDaily.com.

Visbiome clinical trial : ExeGi Pharma said that researchers at Columbia University Irving Medical Center and the University of Pittsburgh will be studying the company’s probiotic product Visbiome in multiple sclerosis (MS) patients in a new clinical trial. The clinical trial will look into the effects of probiotics on the gut microbiota and immune systems […]

The post ExeGi Pharma announces probiotic Visbiome clinical trial in MS patients appeared first on PharmaNewsDaily.com.

Ofev FDA approval for SSc-ILD : The US Food and Drug Administration (FDA) has extended approval for Boehringer Ingelheim Pharmaceuticals’ Ofev (nintedanib) capsules for the treatment of a particular condition associated with systemic sclerosis or scleroderma. The latest FDA approval for Ofev is for its use in slowing the rate of decline in pulmonary function […]

The post Boehringer Ingelheim bags Ofev FDA approval for SSc-ILD appeared first on PharmaNewsDaily.com.